Intracranial efficacy of HER3-DXd in patients with previously treated advanced EGFR-mutated NSCLC: Results from HERTHENA-Lung01

被引：4

作者：

Johnson, M. L. ^{[1
]}

Janne, P. A. ^{[2
]}

Goto, Y. ^{[3
]}

Yoh, K. ^{[4
]}

Lee, S-H. ^{[5
,6
]}

Paz-Ares, L. ^{[7
]}

Besse, B. ^{[8
]}

Novello, S. ^{[9
]}

Hayashi, H. ^{[10
]}

Kim, D-W. ^{[11
,12
]}

John, T. ^{[13
]}

Kao, S. C-H. ^{[14
]}

Felip, E. ^{[15
,16
]}

Yang, J. C-H. ^{[17
]}

Reck, M. ^{[18
]}

Dong, Q. ^{[19
]}

Sporchia, A. ^{[19
]}

Sternberg, D. W. ^{[19
]}

Yu, H. A. ^{[20
]}

机构：

[1] Sarah Cannon Res Inst, Tennessee Oncol, Nashville, TN USA

[2] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA USA

[3] Natl Canc Ctr Hosp, Thorac Oncol Dept, Chuo Ku, Chuo City, Japan

[4] Natl Canc Ctr Hosp East, Dept Thorac Oncol, Kashiwa, Chiba, Japan

[5] Sungkyunkwan Univ, Div Hematol Oncol, Dept Med, Samsung Med Ctr,Sch Med, Seoul, South Korea

[6] Sungkyunkwan Univ, Samsung Adv Inst Hlth Sci & Technol, Dept Hlth Sci & Technol, Seoul, South Korea

[7] Univ Complutense & Ciberonc, Hosp Univ 12 Octubre, Spanish Natl Canc Res Ctr, Madrid, Spain

[8] Univ Paris Saclay, Gustave Roussy, Villejuif, France

[9] Univ Turin, San Luigi Hosp Orbassano, Dept Oncol, Orbassano, Italy

[10] Kindai Univ, Dept Med Oncol, Osaka, Japan

[11] Seoul Natl Univ, Dept Internal Med, Coll Med, Seoul, South Korea

[12] Seoul Natl Univ Hosp, Seoul, South Korea

[13] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia

[14] Univ Sydney, Sydney Med Sch, Chris OBrien Life House, Sydney, NSW, Australia

[15] Vall dHebron Univ Hosp, Med Oncol Serv, Lung Canc Unit, Barcelona, Spain

[16] Vall dHebron Inst Oncol, Barcelona, Spain

[17] Natl Taiwan Univ Hosp, Dept Med Oncol, Taipei, Taiwan

[18] Airway Res Ctr North, German Ctr Lung Res, LungenClin, Grosshansdorf, Germany

[19] Daiichi Sankyo Inc, Oncol Clin Dev, Basking Ridge, NJ USA

[20] Mem Sloan Kettering Canc Ctr, Dept Med, Med Oncol, New York, NY USA

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.2353

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1319MO

引用

页数：2

共 50 条

[31] Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interim results of DESTINY-Lung01.
Smit, Egbert F.
Nakagawa, Kazuhiko
Nagasaka, Misako
Felip, Enriqueta
Goto, Yasushi
Li, Bob T.
Pacheco, Jose Maria
Murakami, Haruyasu
Barlesi, Fabrice
Saltos, Andreas Nicholas
Perol, Maurice
Udagawa, Hibiki
Saxena, Kapil
Shiga, Ryota
Guevara, Ferdinand M.
Acharyya, Suddhasatta
Shahidi, Javad
Planchard, David
Janne, Pasi A.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[32] Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase 3 study TROPIONLung01
Atmaca, A.
Ahn, M.
Lisberg, A.
Paz-Ares, L.
Cornelissen, R.
Girard, N.
Pons-Tostivint, E.
Baz, D.
Sugawara, S.
Cobo, M.
Perol, M.
Mascaux, C.
Poddubskaya, E.
Kitazono, S.
Hayashi, H.
Sands, J.
Hall, R.
Zhang, Y.
Zebger-Gong, H.
Okamoto, I
Schumann, C.
PNEUMOLOGIE, 2024, 78 : S99 - S99
[33] Telisotuzumab vedotin (Teliso-V) in combination with osimertinib in patients with advanced EGFR-mutated, c-met overexpressing, non-small cell lung cancer (NSCLC): Safety and efficacy results from phase Ib study
Horinouchi, H.
Goldman, J. W.
Cho, B. C.
Tomasini, P.
Dunbar, M.
Hoffman, D.
Parikh, A.
Blot, V.
Camidge, D. R.
ANNALS OF ONCOLOGY, 2022, 33 : S1592 - S1592
[34] Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01
Ahn, M-J.
Lisberg, A. E.
Paz-Ares, L.
Cornelissen, R.
Girard, N.
Pons-Tostivint, E.
Vicente Baz, D.
Sugawara, S.
Cobo Dols, M.
Perol, M.
Mascaux, C.
Poddubskaya, E.
Kitazono, S.
Hayashi, H.
Sands, J.
Hall, R.
Zhang, Y.
Zebger-Gong, H.
Uema, D.
Okamoto, I.
ANNALS OF ONCOLOGY, 2023, 34 : S1665 - S1666
[35] Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01
Ahn, M. J.
Lisberg, A.
Paz-Ares, L.
Cornelissen, R.
Girard, N.
Pons-Tostivint, E.
Baz, D. Vicente
Sugawara, S.
Dols, M. Cobo
Perol, M.
Mascaux, C.
Poddubskaya, E.
Kitazono, S.
Hayashi, H.
Sands, J.
Hall, R.
Zhang, Y.
Zebger-Gong, H.
Uema, D.
Okamoto, I.
ANNALS OF ONCOLOGY, 2023, 34 : S1305 - S1306
[36] Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01
Atmaca, Akin
Ahn, Myung-Ju
Lisberg, Aaron
Paz-Ares, Luis
Cornelissen, Robin
Girard, Nicolas
Pons-Tostivint, Elvire
Baz, David Vicente
Sugawara, Shunichi
Cobo, Manuel Angel
Perol, Maurice
Mascaux, Celine
Poddubskaya, Elena
Kitazono, Satoru
Hayashi, Hidetoshi
Sands, Jacob
Hall, Richard
Zhang, Yong
Zebger-Gong, Hong
Uema, Deise
Okamoto, Isamu
Reinmuth, Niels
ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 245 - 245
[37] Osimertinib in Relapsed EGFR-Mutated, T790M-Negative Non-Small Cell Lung Cancer (NSCLC) Patients: Results from the TREM-Study
Eide, I. J.
Helland, A.
Borrisova, S.
Ekman, S.
Cicenas, S.
Koivunen, J.
Gronberg, B. H.
Brustugun, O. T.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2140 - S2141
[38] Subcutaneous amivantamab and lazertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Results from the phase 2 PALOMA-2 study.
Lim, Sun Min
Tan, Jiunn-Liang
Dias, Josiane Mourao
Voon, Pei Jye
How, Soon Hin
Zhou, Xiangdong
Xiong, Hailin
Massuti, Bartomeu
Medley, Louise C.
Nagasaka, Misako
Vicente, David
Girard, Nicolas
Rittmeyer, Achim
Botesteanu, Dana-Adriana
Alhadab, Ali
Mahoney, Janine M.
Zhang, Jie
Bauml, Joshua Michael
Baig, Mahadi
Scott, Susan Combs
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA8612 - LBA8612
[39] Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial
Chmielecki, Juliann
Mok, Tony
Wu, Yi-Long
Han, Ji-Youn
Ahn, Myung-Ju
Ramalingam, Suresh S.
John, Thomas
Okamoto, Isamu
Yang, James Chih-Hsin
Shepherd, Frances A.
Bulusu, Krishna C.
Laus, Gianluca
Collins, Barbara
Barrett, J. Carl
Hartmaier, Ryan J.
Papadimitrakopoulou, Vassiliki
NATURE COMMUNICATIONS, 2023, 14 (01)
[40] Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial
Juliann Chmielecki
Tony Mok
Yi-Long Wu
Ji-Youn Han
Myung-Ju Ahn
Suresh S. Ramalingam
Thomas John
Isamu Okamoto
James Chih-Hsin Yang
Frances A. Shepherd
Krishna C. Bulusu
Gianluca Laus
Barbara Collins
J. Carl Barrett
Ryan J. Hartmaier
Vassiliki Papadimitrakopoulou
Nature Communications, 14

← 1 2 3 4 5 →